TY - JOUR
T1 - Undisclosed antiretroviral drug use in Botswana
T2 - Implication for national estimates
AU - Moyo, Sikhulile
AU - Gaseitsiwe, Simani
AU - Powis, Kathleen M.
AU - Pretorius Holme, Molly
AU - Mohammed, Terence
AU - Zahralban-Steele, Melissa
AU - Yankinde, Etienne K.
AU - Maphorisa, Comfort
AU - Abrams, William
AU - Lebelonyane, Refeletswe
AU - Manyake, Kutlo
AU - Sekoto, Tumalano
AU - Mmalane, Mompati
AU - Gaolathe, Tendani
AU - Wirth, Kathleen E.
AU - Makhema, Joseph
AU - Lockman, Shahin
AU - Clarke, William
AU - Essex, Max
AU - Novitsky, Vlad
N1 - Funding Information:
We thank the study participants and entire BCPP staff including all the field study teams for making this study a success. We thank the BCPP team members for their contribution to this study. We thank Lendsey Melton for excellent editorial assistance. We thank the Ministry of Health and CDC Botswana for their excellent support and contributions to the study. We thank Michelle Roland for helpful critique and discussion. This study was supported by the US President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement U01 GH000447. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. S.M. was supported by the Fogarty International Center and National Institute of Mental Health, of the National Institutes of Health under Award Number D43 TW010543. S.M. and S.G. were partially supported by sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant #107752/Z/15/Z) and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust, or the UK government. The funders had no role in the study design, data collection, and decision to publish, or in the preparation of the article.
Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/7/17
Y1 - 2018/7/17
N2 - Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.
AB - Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.
UR - http://www.scopus.com/inward/record.url?scp=85050239050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050239050&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000001862
DO - 10.1097/QAD.0000000000001862
M3 - Article
C2 - 29762166
AN - SCOPUS:85050239050
SN - 0269-9370
VL - 32
SP - 1543
EP - 1546
JO - AIDS
JF - AIDS
IS - 11
ER -